{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134757","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.061827+00:00","generated_at":"2026-05-29T05:11:50.785248+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OKI-219 well-tolerated in first human trial; no hyperglycemia, Part 1b combo initiated","bullets":["17 patients dosed across 300–900 mg BID; no dose interruptions, reductions, or discontinuations.","Only Grade 1 TRAEs reported (diarrhea, nausea, pruritus); no hyperglycemia observed.","900 mg BID achieved steady-state PK with near-continuous EC80 coverage for pAKT inhibition.","Two HR+/HER2- breast cancer patients on 300 mg showed >7 months stable disease; one had >95% ctDNA reduction.","Part 1b evaluating OKI-219 + fulvestrant initiated; single-agent/combination data expected 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134757","json":"https://secwatch.observer/filing/0000950170-24-134757.json","markdown":"https://secwatch.observer/filing/0000950170-24-134757.md","text":"https://secwatch.observer/filing/0000950170-24-134757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024134757/0000950170-24-134757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024134757/okur-20241210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:11:50.785248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}